Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | CDK20 |
| Gene Name: | CDK20 |
| Protein Full Name: | Cell division protein kinase 20 |
| Alias: | CDK-activating kinase p42;Cell cycle-related kinase;Cell division protein kinase 20;Cyclin-dependent protein kinase H;Cyclin-kinase-activating kinase p42 |
| Mass (Da): | 38695 |
| Number AA: | 346 |
| UniProt ID: | A2A390 |
| Locus ID: | 23552 |
| COSMIC ID: | CDK20 |
| Gene location on chromosome: | 9q22.1 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 538 |
| Percent of cancer specimens with mutations: | 0.18587360595 |
| Normal role description: | CDK20 is a protein-serine/threonine kinase. As a cyclin dependent kinase, it regulates G1-to-S phase progression. CDK20 phosphorylates and activates CDK2. CDK20 is an anti-apoptotic protein necessary for cell growth. CDK20 has been demonstrated in vitro to induce oncogenesis and CDK20 knockouts prevent tumour progression. Expression levels increased in tumour cells compared to normal tissue. |